http://www.biomonitor.dk Wed, 01 Sep 2010 12:36:13 +0000 http://backend.userland.com/rss092 en ARUP Laboratories (Salt Lake City, USA) and Biomonitor A/S (Copenhagen, Denmark) Form Partnership in Personalized Medicine to Monitor Multiple Sclerosis Patients in the USA for Neutralizing Antibodies to IFN-beta Using Biomonitor's iLiteTM Reporter Gene Technology. Click here for further details http://www.biomonitor.dk/?p=161 We are pleased to announce that as of July 2010, the Danish Medicines Agency has granted Biomonitor A/S a GLP-authorization. For further information please contact: Arsalan Kharazmi, CEO, Biomonitor A/S. E-mail: ak @ biomon.dk, Phone: +45 39179797 http://www.biomonitor.dk/?p=149 Biomonitor is proud to present the first IVD cell-based assay kits for NAb detection  iLiteTM anti-human IFN-beta-1a - used  for the detection of Neutralizing antibodies against IFN-beta-1a                                                                     and  iLiteTM anti-human IFN-beta-1b - used  for the detection of Neutralizing antibodies against IFN-beta-1b  Prolonged therapies with many biopharmaceuticals, including IFN-alpha and IFN-beta, often lead to development ... http://www.biomonitor.dk/?p=148 We are pleased to announce that as of June 2010, the laboratories of Biomonitor A/S have been classified for working with genetically modified organisms (GMO). For further information please contact: Arsalan Kharazmi, CEO, Biomonitor A/S. E-mail: ak @ biomon.dk, Phone: +45 39179797 http://www.biomonitor.dk/?p=147 We are pleased to announce that as of March 2010, Biomonitor A/S has completed Round C private placement with the Danish venture capital company Sunstone Capital A/S. For further information please contact: Arsalan Kharazmi, CEO, Biomonitor A/S. E-mail: ak @ biomon.dk, Phone: +45 39179797 Søren Lemonius, Partner, Sunstone Capital A/S, E-mail: Lemonius @ ... http://www.biomonitor.dk/?p=146 Please download the press release for further details. We are pleased to announce that Biomonitor has acquired Neutekbio Ltd. on 27. November 2008. Neutekbio has a proprietary platform of products based on reporter gene technology and developed cell-based assays and kits called iLite™ , which complement Biomonitor's offerings in assays for patient monitoring and biopharmaceutical drug ... http://www.biomonitor.dk/?p=82 We are pleased to announce that the Danish venture capital company Sunstone Capital A/S has invested in our company. Biomonitor A/S is with this investment ready to go after the $ 800M theranostics market for screening for antibodies against biopharmaceuticals. Please download the press release for details. For further information please contact: Arsalan Kharazmi, CEO, Biomonitor A/S.  E-mail: ... http://www.biomonitor.dk/?p=75 Biomonitor's work within immunogenicity of therapeutic proteins has been recognized by the European Medicines Agency (EMEA) EMEA have formulated a set of “Guidelines On The Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins” that came into effect on 31. july 2007. An abstract of the guidelines on immunogenicity is provided below and ... http://www.biomonitor.dk/?p=37 In a draft publication, Guidelines on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins, the European Medicines Agency (EMEA) now recognizes Immunogenicity as an essential element to investigate when treating patients with therapeutic proteins and peptides. http://www.biomonitor.dk/?p=1 In a paper published in Arthritis and Rheumatism, Bendtzen & coworkers used Biomonitor's RIA's for infliximab/Remicade® and anti-infliximab Ab to monitor RA patients. They demonstrated the high frequency of patients with Ab, and they showed that development of antibodies, heralded by low pre-infusion serum-infliximab levels, is associated with increased risk ... http://www.biomonitor.dk/?p=60